Duration of Medication Therapy and Outcomes After Holmium Laser Prostate Surgery for Patients With Benign Prostatic Hyperplasia (BPH)

Stopped early

Conditions studied: Benign Prostatic Hyperplasia

In brief

To determine if the prior prolonged use of medication, as a treatment for benign prostatic hyperplasia, reduces the efficacy of Holmium laser enucleation of the prostate (HoLEP) for patients with benign prostatic hyperplasia (BPH).

Key facts

Study ID

NCT03768765

Run by

University of Kansas Medical Center

People needed

144

Starts

2018-11-15

Expected to finish

2024-08-27

Last updated by the study team

2024-10-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be 18 years of age or older
• Patients must present to clinic with a diagnosis of benign prostatic hyperplasia with lower urinary tract symptoms
• Patients must be scheduled to undergo a holmium laser prostate surgery (enucleation or ablation)

You may not qualify if…

• Patients who are under 18 years of age are not eligible.
• Patients who have a diagnosis of bladder cancer are not eligible.
• Patient who have a diagnosis of prostate cancer are not eligible.
• Patients with an elevated prostate-specific antigen (PSA) suggesting prostate cancer are not eligible unless patient has prior negative prostate biopsy.
• Patients who have acute prostatitis, a prostate abscess, or neurogenic bladder are not eligible

Where it is running

• University of Kansas Health System — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.